扎鲁司特治疗哮喘

目的 :观察扎鲁司特对哮喘的临床疗效。方法 :176例非急性发作期哮喘病人均给扎鲁司特2 0mg ,po ,bid ,疗程 6wk。观察临床疗效、肺功能变化和不良反应。结果 :1秒钟用力呼气量(FEV1)、呼气流量峰值 (PEF)治疗后wk 2 ,4 ,6末与治疗前比较 ,差异均有非常显著意义 (P <0 .0 1) ;其中轻度组和中度组早晨PEF增加较重度组更为显著 (P <0 .0 5 ) ,轻度组和中度组PEF日内波动率较重度组下降更为显著 (P <0 .0 1)。治疗后 ,临床控制 5 0例 (2 8.4 % ) ,显著改善 92例 (5 2 .3% ) ,改善 2 5例 (14.2 % ) ,无效 9例 (5 .1% ) ,其中轻度组和中度组疗效较重度组更佳 (P <0 .0 5 ) ,激素低敏感型 (SI)哮喘病人临床有效率达 10 0 %。未见严重不良反应。结论 :扎鲁司特对哮喘是一种新型的、安全、有效的抗炎和平喘药物

Zafirlukast in treatment of asthma

AIM: To observe the effect of zafirlukast in the treatment of asthma. METHODS: One hundred and seventy-six patients with asthma were treated with zafirlukast 20 mg, bid for 6 wk. Clinical effects, pulmonary function change and adverse reactions were observed. RESULTS: Forced expiratory volume in one second(FEV 1) and peak expiratory flow (PEF) gradually increased in the treatment of zafirlukast (P<0.01). PEF at dawn increased more remarkably in mild and moderate groups than that in severe group (P<0.05), and rate of PEF fluctuation decreased more remarkably in mild and moderate group than that in severe group (P< 0.01) after the treatment of zafirlukast. And the treatment shew that fifty patients (28.4 %) were clinically controlled ninety-two patients (52.3 %) were remakably improved, twenty-five patients (14.2 %) were improved, nine patients (5.1 %) were ineffective. The clinical effect was better in mild and moderate group than that in severe group (P< 0.05). The clinical effective rate in SI patients was 100 %. No serious adverse reactions were found in the patients. CONCLUSION: Zafirlukast was a new, safe and effective drug in treating patients with asthma.